Q3 2025 Photocure ASA Earnings Call Transcript
Key Points
- PhotoCure ASA (PHCUF) reported a 12% year-over-year increase in global product revenue, with North America showing a 14% unit growth.
- The company achieved its 10th consecutive quarter of positive EBITDA, with NOK10.2 million in Q3 2025.
- PhotoCure ASA (PHCUF) has a strong balance sheet with NOK247.8 million in cash and no term debt.
- The strategic partnership with Intelligence Scopes Corporation aims to develop AI software for real-time tumor detection, enhancing the company's position in precision diagnostics.
- The company is expanding its geographic footprint and leveraging distribution partnerships, with significant growth in Europe, particularly in the Nordics, Germany, and France.
- The decline in the Flex surveillance market continues to impact sales, with Flex now representing less than 5% of total sales.
- Foreign exchange impacts negatively affected revenue growth, with a 14% growth reduced to 12% due to currency fluctuations.
- The US market remains significantly underpenetrated, with less than 10% market share, indicating a need for increased market penetration efforts.
- The company faces challenges with the FDA reclassification process, which could delay the entry of additional blue light OEM partners into the US market.
- The government shutdown in the US has delayed FDA submissions for new scope manufacturers, potentially impacting future growth.
All right. Well, welcome to Photocure's third quarter 2025 results. I'm Dan Schneider, President and CEO, and with me today is Erik Dahl, our CFO. A reminder the usual disclaimers are in effect for today's presentation. So I'd like to start with this slide, the strategic priorities and initiatives. It's our guide to how we execute and allocate resources across the company. At a high level. Our strategy is centered around three key pillars strengthening the core Cysview business, advancing blue light cystoscopy as a definitive standard of care in bladder cancer, and expanding our reach into the broader neuro oncology and precision diagnostic space.
The first pillar, accelerate and expand is about delivering on our financial guidance for disciplined growth in revenue and EBITDA in our core business and to continue generating operating leverage, which we continue to do so. It's also about driving the blue light cystoscopy mobile strategy for tech in the US and increasing penetration in the EU, particularly in the priority growth markets France, Italy,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
